This week we look at a new migraine medicine, a rescheduling of cannabidiol for epilepsy and a successful trial for neuromyelitis optica spectrum disorder.
Browsing: Epilepsy and seizure
GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Hannah Cock provides insight into the current data, controversies and pipelines for the use of cannabis-derived therapeutics in epilepsy.
Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week
A study into children with epileptic encephalopathy has uncovered associated genes, which could lead to the development of novel treatment strategies.
Listen to our latest NCTalks podcast with leading neurosurgeon, Ali Rezai, to hear more about his work, how neuromodulation can be harnessed to treat ‘alternative’ conditions, and where he hopes the field will progress in the next decade.
Neural activity resembling epileptic events has been found in multiple GCaMP6-expressing transgenic mouse lines, potentially complicating interpretation of neural activity in the lines.
This communication examines the association between the number of seizures in refractory epileptic patients and potential interactions between their antiepileptic medications and single nucleotide polymorphisms.
This Review looks at the literature surrounding recent neurophysiological techniques and novel surgical tools in pediatric epilepsy.
Zebinix (eslicarbazepine acetate) has received market authorization as a once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy.